<DOC>
	<DOC>NCT00878462</DOC>
	<brief_summary>This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication. Patients received 6 total doses of study drug (2 doses of each asenapine formulation) over 3 consecutive days: 2 different formulations each day, 1 in the morning and 1 in the evening. The formulations were: white unflavored, white raspberry flavored, and red raspberry flavored. Patients were given a questionnaire following each dose of study medication (one questionnaire twice per day for 3 days) to measure how acceptable each formulation was.</brief_summary>
	<brief_title>An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)</brief_title>
	<detailed_description>Study drug was administered according to a random selected sequence schedule with 2 constraints: Subjects did not receive consecutive doses of the same formulation, and each formulation was given once in the morning and once in the evening over the course of the 3-day treatment period.</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>are at least 18 years of age and of legal minimum age for trial participation; are a male, or a female who is not of childbearing potential are free from an acute exacerbation of psychosis for at least 3 months; have a current DSMIV diagnosis of schizophrenia (paranoid, disorganized, catatonic, or undifferentiated subtype), or schizoaffective disorder; delusional disorder, major depressive disorder, or bipolar disorder, for whom chronic antipsychotic therapy is indicated; correctly identify 3 out of 4 basic flavors (bitter, sweet, salty, or sour) on a neutral taste paradigm; are receiving oral antipsychotic medication. an uncontrolled, unstable clinically significant medical condition clinically significant abnormal laboratory, vital sign, PE, or ECGs findings at Screening; previously experienced NMRB (also known as vasovagal reflex) or sensitivity for fainting; a positive serum pregnancy test at screening, or the intention to become pregnant within the next 30 days; a history of seizures; a history of neuromalignant syndrome; a current (past 6 months) substance abuse or dependence according to DSMIVTR criteria (excluding nicotine); an imminent risk of selfharm or harm to others; currently receiving a depot antipsychotic, such as fluphenazine decanoate, haloperidol decanoate, or Risperdal Consta, within at least 1 dosing cycle of Day5; any impairment in taste functioning; receiving lithium or topiramate; judged by the principal investigator (PI) to be unable to reliably respond to the questionnaire based on clinically significant cognitive impairment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>